Generics and Patent Strategies 2014

Key Topics

• The Impact of Asian markets on the European generics industry
• Challenges of API synthesis and new EU Bioequivalence guidelines
• Strategies around Ever-greening practices employed by innovator companies to stave off Generic Competition
• The outcome of AstraZeneca’s filing for a breach of patent surrounding their gastro-protective compound Omeprazole
• Changes in regulatory affairs in key global markets

Who should Attend

• Managing Director
• Head of Regulatory affairs
• VP, Research
• VP, Clinical
• Principal Scientist
• Medical Affairs Director
• Legal Council
• Clinical Regulatory Strategy Manager
• Chief Scientific Officer
• Clinical Pharmacologist
• Brand Manager
• Medical Director
• Commercial Director
• Head of Pharmacology
• Chief Medical Officer
• VP Chemistry
• Head of Clinical Science
• Head Global Licensing
• Consultants
• Director of Medical Affairs
• Chief Executive Officer
• Associate Clinicians
• Business Development Directors
• Vice President